99--Test efficaciousness of a number of potential stoichiometric and catalytic enzymes as pretreatments against the toxcity of chemical warfare nerve agents in vivo in animal models.

The US Army Medical Research Acquisition Activity (USAMRAA) intends to award a firm-fixed-price contract spanning 36 months, divided into a base period plus five optional six-month ordering periods, to fulfill a procurement need for the US Army Medical Research Institute of Chemical Defense (USAMRICD) at Aberdeen Proving Grounds, Maryland. This contract focuses on the continued purchase of commercially available purified recombinant adenoviruses, which are essential for ongoing research protocols that directly build upon prior work conducted by Welgen Incorporated. Maintaining continuity with Welgen is critical, as shifting to a new vendor risks compromising experimental consistency and research outcomes due to potential differences in product processes. The acquisition strategy follows the authority outlined in the Federal Acquisition Regulation and involves no public solicitation of bids; instead, the government signals an intent to award a sole-source contract to avoid interruptions in critical research on chemical warfare nerve agent countermeasures. Interested firms capable of meeting the government’s requirements were invited to submit capability statements by June 5, 2012, after which the contract award process would proceed if no alternative responses emerged. The contract’s technical scope includes testing the effectiveness of various stoichiometric and catalytic enzymes as pretreatments against the toxicity of nerve agents in animal models, under NAICS code 541711. This followed approach emphasizes ensuring the research mission at USAMRICD continues uninterrupted with proven materials and suppliers.